3 курс / Фармакология / Антисекреторные препараты

Комаров Б.Д., Матюшенко А.А., Кириенко А.И.

Прободная язва желудка и двенадцати­

перстной кишки. В кн.: Руководство по не­ отложной хирургии органов брюшной по­ лости (под ред. B.C. Савельева). М., 2004, с. 303-326.

Костюченко А.Л., Гуревич К.Я., Лыткин М.И. Ин­ тенсивная терапия послеоперационных

осложнений. СПб., 2000,575 с.

Кубышкин В.А., Шишин К.В. Эрозивно-язвенное

поражение верхних отделов желудочно-

кишечного тракта в раннем послеопераци­ онном периоде. Consilium medicum, 2004,

№1,с. 29-32.

Курыгин А.А., Румянцев В.В. Ваготомия в хирур­

гической гастроэнтерологии. Спб.: Гиппо­ крат, 1992. С. 362.

Курыгин А.А., Скрябин О.Н. Острые послеопера­

ционные гастродуоденальные язвы. С.-Пб., 1996,370 с.

Лазебник Л.Б., Васильев Ю.В. Проект. Терапия кислотозависимых заболеваний (Первое

Московское соглашение, 5 февр.2003 г.) // Эксперимент, иклинич. гастроэнтерология.- 2003.-№4.

Лапина Т.Л. Лечение эрозивно-язвенных пора­ жений желудка и двенадцатиперстной киш­ ки. РМЖ, том 9, № 13-14, 2001.

Лин Хвай, Ло Вен, Лии Фа и др. Проспективное рандомизированное сравнительное иссле­ дование, показывающее, что омепразол предупреждает повторное кровотечение у пациентов с кровоточащей пептической яз­ вой после успешного эндоскопического ис­

следования. JAMA - Russia, 1998, № 11 (1), с. 32 - 35.

Лопина О.Д. Механизм действия ингибиторов протонного насоса // Российский журнал

гастроэнтерологии, гепатологии, колопрок-

тологии, 2002, №2, с. 38-44.

Панцырев Ю.М., Михалев А.И., Федоров Е.Д., Чернякевич С.А. Хирургическое лечение осложненной язвенной болезни. В сб.: 50

лекций по хирургии (под ред. B.C. Савелье­ ва). М., 2003, с. 248 - 258.

Пиманов CJ/L Эзофагит, гастрит, язвенная бо­ лезнь. Н.Новгород, 2000, 377 с.

Сацукевич В.Н. Факторы риска острых ослож­

нений гастродуоденальных язв. М: Либерия 1999

Секачева М.И. Антисекреторные препараты в

лечении неварикозных кровотечений из верхних отделов ЖКТ с точки зрения дока­

зательной медицины. Consilium medicum,

2004, том 6, №6, с. 386-389.

Современные проблемы экстренного и пла­

нового хирургического лечения больных язвенной болезнью желудка и двенадцати­

перстной кишки. Материалы конференции.

Саратов, 2003, с. 30 - 94.

Столпман Н., Метц Д.С. Патофизиология и про­ филактика стрессовых язву послеопераци­ онных больных. РМЖ, 2005, том 13, № 25, с.

1668-1674.

Юдин С.С. Этюды желудочной хирургии. М.,

«Медицина», 1965, с. 189 - 190 .

Яицкий Н.А., Седов В.М., Морозов В.П. Язвы

желудка и двенадцатиперстной кишки. M.,

«Мед-пресс информ», 2002,376 с.

Abelo A., Andersson Т. В., Bredberg Е. et al. Stereo­ selective metabolism by human liver CYP en­ zymes of a substituted benzimidazole // Drug Metab. Dispos. — 2000. — Vol. 28. — P. 58-64.

Abelo A, Andersson ТВ, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective me­ tabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28:

966-972.

Andersson T, Hassan-Alin M, Hasselgren G, R hss K, Weidolf L. Pharmacokinetic studies with esomeprazole , the (S)-isomer of omeprazole.

Clin Pharmacokinet 2001; 40:411-426. Andersson Т., Bredberg E., Sunzel M. etal. Pharma­

cokinetics and effect on pentagastrin stimu­ lated peak acid output of omeprazole and its 2 optical isomers, S-omeprazole/esomeprazole and R-omeprazole//Gastroenterol. — 2000. — Vol. 118.—A1210

Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton-pump inhibition in high-risk patients with acute pep­ tic ulcer bleeding. Aliment Pharmacol Ther 2005;21:677-686.

Barkun A, et al. Scand J Gastroenterol 2008; 43

(Suppl244):P11.

Barkun A., Bardou M., Marshall J._Consensus Rec­ ommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding,

2003.

Castell D.O., Kahrilas P.J., Richter J.E. etal. Esomeprazole is more effective than lansoprazole for treating daily and nocturnal heartburn (HB) in GERD patients with erosive esophagitis (EE) //

J. Gastroenterol. Hepatol. — 2002. — Vol. 17

(Suppl.).—A232.

Church N., Palmer K. Ulcers and nonvariceal bleed­ ing. Endoscopy, 2003;35:22-6.

Creutzfeldt W. Chiral switch a successful way for developing drug: Example of esomeprazole // Z. Gastroenterol. — 2000. — Vol. 38. — P. 893897.

Daneshmend TK, Hawkey CJ, Langmann MJS, Lo­ gan RFA, Long RG, Walt RP. Omeprazole ver­ sus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992;304:143-147.

GentaR.M., Magner D.J., D'Amico D. Safety of longterm treatment with a new PPI esomeprazole in GERD patients // Gastroenterol. — 2000. — Vol. 118. — A16.

Gerson L.B., Robbins A.S., Garber A. et al. A costeffectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease//Am. J. Gastroenterol. — 2000. — Vol. 95, №2. — P. 395-407.

Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Ef­ fect of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemor­ rhage. Gastroenterology 1978;74:38-43.

Hassan-Alin M., Andersson Т., Bredberg E., Rohss K. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects // Eur. J. Clin. Pharmacol. — 2000. — Vol. 56. — P. 665-670.

Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Scand J Gastroenterol. 1997;32:328-332.

Список литературы

Hasselgren G., Rohss K., Hedenstrom H. Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symp­ toms of GERB. Digest. Diseases And Sciences, Vol. 47, No. 5, 2002.

Hasslegren G., Hassan-Alin M., Andersson T. et al. Pharmacokinetics of esomeprazole are unal­ tered in the elderly // Gut. — 2000. — Vol. 47 (Suppl. III).— A62.

Johnson D.A., Benjamin S.B., Vakil N.B. et al. Es­ omeprazole once daily for 6 months is effec­ tive therapy for maintaining healed erosive esophagitis and for controlling gastroesopha­ geal reflux disease symptoms: A randomized double-blind, placebo-controlled study of efficacy and safety // Am. J. Gastroenterol. — 2001. — Vol. 96. — P. 27-34.

Kahrilas P.J., Kalk J.V., Johnson D.A. et al. Esome­ prazole impoves healing and symptom i s o l a ­ tion as compared with omeprazole in reflux oe­ sophagitis patients: A randomized controlled trial // Aliment. Pharmacol. Ther. — 2000. — Vol. 14. —P. 1249-1258.

Kauffman GL, Conter RL. Stress ulcer and gastric ulcer. In: Greenfield LJ, Mulholland MW, Old­ ham KT, Zelenock GB, Lillemoe KD, editors. Surgery: scientific principles and practice. 2nd ed. Philadelphia: Lippincott-Raven;1997. p. 773-88.

Khuroo M., Yattoo G., Javid G. et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N. Engl. J. Med. 1997; 336:1054-1058.

Kromer W., Horbach S., Luhmann R. Relative effi­ cacies of gastric proton pump inhibitors: Their clinical and pharmacological basis // Pharma­ cology. — 1999. — Vol. 59. — P. 57-77.

Lanas A, Artal A, Bias J, et al. Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer. J Clin Gastroenterol. 1995;21:103-106.

Lau JY, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med., 2000, 343:310.

Lau JY, Leung WK, Wu JC, et al. Early administra­ tion of high-dose intravenous omeprazole prior to endoscopy in patients with upper gas-

trointestinal bleeding: a double blind placebo controlled randomized trial. Gastroenterology

2005;128:Suppl 2:A-50

Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A Pro­ spective Randomized Comparative Trial Show­ ing That Omeprazole Prevents Rebleeding in

Patients With Bleeding Peptic Ulcer After Suc­ cessful Endoscopic Therapy. Arch Intern Med, 1998; 158: 54-58.

Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A Pro­ spective Randomized Comparative Trial Show­ ing That Omeprazole Prevents Rebleeding in

Patients With Bleeding Peptic Ulcer After Suc­ cessful Endoscopic Therapy. Arch Intern Med,

1998; 158: 54-58.

Lind Т., Junghard O., Lauritsen K. Esomeprazole and lansoprazole in the management of pa­ tients with reflux oesophagitis (RO): Combinig results from two clinical studies // J. Gastroen­ terol. Hepatol. — 2002. — Vol. 17 (Suppl.). —

A1024.

Lind Т., Rydberg L., KylebackA. etal. Esomeprazole provides imroved acid control versus omepra­ zole in patients with symptoms of g a s t r o e ­ sophageal reflux disease // Aliment. Pharma­ col. Ther. — 2000. — Vol. 14. — P. 861-867.

Marino P. The ICU Book. Philadelphia: Lea&Febiger, 1991.

Metz D. C. et al. Am. J. Gastroenterol. 2000; 95, 3: 626-633.(9)

Miner P et al. Am J Gastroenterol 2006;101:404-5

Miner Ph., Katz Ph., Cheng Y. Gastric acid control with esomeprazole, lansoprazole, omeprasole, pantoprazole and rabeprasole: a five-way crossover study. The Am. Journal of Gastroen­ terology. Vol. 98. No. 12, 2003.

Netzer P, Gaia C, Sandoz M, et al. Effect of repeated injection and continuous infusion of omeprazole and ranitidine on intragastric pH over 72 hours.

Am J Gastroenterol 1999;94:351-357.

Richter J.E., Kahrilas P.J., Johanson J. et al. Ef­ ficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: A randomized controlled trial //

Amer. J. Gastroenterol. — 2001. — Vol. 96. — P. 656-665.

Rohss K., Claar-Nilsson C, Rydholm H. Esomepra­ zole 40 mg provides more effective acid control than lansoprazole 30 mg // Gastroenterol. —

2000.—Vol. 118.—A20.

Rohss K., Lind Т., Wilder-Smith C. Esomeprazole (40 mg) provides more effective intragastric acid control than lansoprazole (30 mg), omeprazole (40 mg), pantoprazole (40 mg), rabeprazole (40 mg) in patients with gastro-oesophageal reflux symptoms. Eur. J. Clin. Pharmacol. (2004), 60: 531-539.

Rohss K., Lundin C, Rydholm H., Nyman L. Es­ omeprazole 40 mg provides more effective acid control than omeprazole 40 mg // Gut. — 2000. — Vol. 47 (Suppl. III). — A63.

Rohss K., Wilder-Smith C.H., Claar-Nilsson C. et al.

Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors // J. Gastroenterol. He­ patol. — 2002. — Vol. 17 (Suppl.). — A228.

Rollhausen C. NSAIDs and upper gastrointestinal bleeding. Endoscopy, 2003; 35: 372-3.

Rollhauser C, Fleischer D. Ulcers and nonvariceal bleeding. Endoscopy, 1999,31 (1), p. 17-25.

R hss K, Bondarov P, Lundin C, Nilsson-Pieschi C, Nyman L, Niazi M. Esomeprazole 40 mg ad­ ministered as a 30-minute intravenous infusion provides the same effective acid control as oral administration in healthy subjects [Abstract].

Gastroenterology 2003; 122 (4Suppl.):A-231.

Schonekas H. et al. Gastroenterology 1999; 116, 4 (Part 2):A305.(16)

Sneider H., Van Rensburg C, Schmidt S. et al. Esomeprazole 40 mg administred intrave­ nously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis. Digestion 2004; 70: 250 - 256.

Sung JJ, etal. Aliment PharmacolTher2008;27:66677.

Sung J J, etal. Scand J Gastroenterol 2008;43(Suppl

244):Or19

Talley N., Vanables Т., Green J. Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopynegative GERD: A placebo-controlled trial of on-demand therapy for 6 months // Gastroen­ terol. — 2000. — Vol. 118. — A658.

Thomson A.B.R., Claar-Nilsson С, Hasselgren G. et al. Esomeprazole 40 mg provides more ef­ fective acid control than lansoprazole 30 mg during single and repeated administration // Gut. — 2000. — Vol. 47 (Suppl. III). — A63.

Tulassay Z., Kryszwski A., Dite P. et al. 7-day treat­ ment with esomeprazole triple therapy eradi­ cates Helicobacter pylori and heales patients with duodenal ulcer disease // Gastroenter­ ol. — 2000. — Vol. 118. — A502.

Tulley N. J., Lauritsen K., Tunturi-Hihnala H. et al. Es­ omeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A controlled trial of «on-de- mand» therapy for 6 months // Aliment. Phar­ macol. Ther. — 2001. — Vol. 15. — P. 347-354.

Tunturi-Hihnala H. et al. Esomeprazole 20 mg main­ tains symptom control in endoscopy-negative gastro-oesophageal reflux disease: A con­ trolled trial of on-demand therapy for 6 months

//Aliment. Pharmacol. Ther. — 2001. — Vol.

15.—P. 347-354.

Vakil N.B., Shaker R., Johnson D.A. et al. The new proton pump inhibitor esomeprazole is effec­ tive as a maintenance therapy in GERD patients with healed erosive oesophagitis: A 6-months, randomized, double-blind, placebo-controlled study of efficacy and safety // Aliment. Phar­ macol. Ther. — 2001. — Vol. 15. — P. 927-935.

Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJS. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992;340:1058-1062.

Walt RP, Reynolds JR, Langman MJ, Smart HL, Kitchingman G, Somerville KW, Hawkey CJ. In­ travenous omeprazole rapidly raises intragas­ tric pH. Lancet 1992;340:1062-1068.

Van Pinxtern В., Numans M.E., Bonis A., Lan S.

Short-term treatment with proton pump inhibi­ tors, H2-receptor antagonist and prokinetics for gastroesophageal reflux disease-like symp­ toms and endoscopy negative reflux disease // Cochrane Database Syst. Rev. - 2000. - 2.

Wilder-Smith C, Bondarov P., Lindgren M. et al. Intravenous esomeprazole (40 mg and 20 mg) inhibits gastric acid secretion as effectively as oral esomeprazole: results of two randomized

Списоклитературы

clinical studies. Eur. Journal of Gastroenterol.

And Hepatol. 2005,17:191-197.

Wilder-Smith C, Rohss K., Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg / / J . Gas­ troenterol. Hepatol. - 2002. - Vol. 17 (Suppl.). -A7845.

Wilder-Smith C.H., Claar-Nilsson C, Hasselgren G.,

Rohss K. Esomeprazole 40 mg provides fac­ tor and effective acid control than rabeprazole 20 mg in patients with symptoms of GERD // J. Gastroenterol. Hepatol. - 2002. - Vol. 17 (Sup­ pl.).-A612.

Wilder-Smith C.H., Rohss K., Lundin C. Esomepra­ zole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg // Gastro­ enterol. - 2000. - Vol. 118. - A22.

ZhonglinY. etal. J. Gastroenterol. Hepatol. 2002; 17

(Suppl): A257.(17).